Yartemlea: A New Hope for Stem Cell Patients
Kilder
- Nature: DynamicAtlas: a morphodynamic atlas for Drosophila development - Nature
- Nature: Effectiveness of the 2024–2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up - Nature
- Nature: GBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma - Nature
- Biospace: Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic - BioSpace
- Biospace: Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease - BioSpace
- Bioworld: FDA approves Omeros’ Yartemlea for stem cell patients - BioWorld MedTech
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.